BACKGROUND: To assess the valve of stress scintigraphy in patients with left bundle branch block(LBBB), patients with LBBB underwent stress scintigraphy, coronary angiography and left ventriculography. METHOD: Exercise(n=12) or pharmacology(n=1) scintigraphy, coronary angiography and left ventriculography were performed in 13 patients(12 men and 1 woman, aged 53-81 years) with LBBB. RESULT: 1) All patients had anteroseptal defects on scintigram. 2) Among these, 3 patients(23%) did not have any significant coronary artery stenosis on coronary angiogram. CONCLUSION: Stress scintigraphic change may not help much in the detection of coronary artery disease(CAD) in patients with LBBB.
Bundle-Branch Block* ; Coronary Angiography ; Coronary Stenosis ; Coronary Vessels ; Female ; Humans ; Male ; Radionuclide Imaging*

No abstract available.
Estrogens, Conjugated (USP)* ; Heart Failure* ; Humans ; Physicians, Primary Care* ; Primary Health Care*

Effects of Pravastatin(Mevalotin(R)), a new HMG-CoA reductase inhibitor on the blood lipids were studied for the period of 3 months in 40 subjects with hypercholesterolemia more than 250mg/dl. Age of the subject was 50 years in average with range of 34 to 72 years. There were 22 cases of male and 18 cases of female. The cause of hyperlipidemia was not specified, but there were no case of liver, thyroid and renal disease. The 10mg of Preavastatin was given in devided doses in the morning and at bed time for 3 months. Serum LDL-cholesterol, total cholesterol, HDL-cholesterol, triglyceride and atherogenic index were measured before and after the medication in every month and following results were obtained. 1) Serum cholesterol decreased maximally at 2months after the medication with average decrease of LDL-cholesterol 79.8mg/dl(43%), serum total cholesterol 99.8mg/dl(34%) and the atherogenic index 3.0(45%). The decrease of total serum cholesterol was dependent on the pretreatment level. 2) The serum triglyceride decreased in average 81mg/dl(26%) in one month after the medication however the change was not statistically significant because of wide variation. 3) The HDL-cholesterol decreased in average 1.6mg/dl(4%) in one month and statistically significant. 4) The serum total cholesterol started to change in 3 days and tended to decrease with unstable variation up to the end of 2 weeks after the medication. In one month after cutting drug, there were slight increase of cholesterol but did not return to control value. 5) The significant effect of blood lipid lowering drug in non-specific hyperlipidemia should be evaluated when the changes are more than intra-individual variation of blood lipids. 6) There were only 2 cases of side effect with epigastric pain and fullness which subsided soon and there was no change in liver functions, serum creatinine and fasting blood sugar after the medication. In conclusion, the pravastatin is an excellent new lipid lowering drug with safety.
Blood Glucose ; Cholesterol ; Creatinine ; Fasting ; Female ; Humans ; Hypercholesterolemia ; Hyperlipidemias* ; Liver ; Male ; Oxidoreductases ; Pravastatin ; Thyroid Gland ; Triglycerides

No abstract available.
Echocardiography*

To evaluate the reproducibility of the Ambulatory Electrocardiography (AECG), we examined the consistency rates of premature beats between the baseline AECG's and the repeat AECG's in 23 patients who underwent AECG's times within 1 year. 12 patients were male and 11 patients were female. Their mean age was 48 years. (Range ; 20 years-75 years) The time interval between both AECG's was 1 month 20 days. (Range ; 1 day-9months) They did not take any antiarrhythmic druge during the observation period except 4 patients who were taking calcium channel blockers or beta receptor blockers for hypertensive heart disease or ischemic heart disease. The consistency rate of both frequency and complexity of ventricular premature beats was 52%. The consisency rate of both frequency and complexity of supraventicular premature beats was 35%. These consistency rates seemed to vary as the time interval between both AECG's differed. In the case of ventricular premature beats, the consistency rates of 1 day, 8 days and 5 months as the time interval were 100%, 38% and 14% respectively. In the case of supraventricular premature beats, the consistency rates were 50%, 25% and 29%. We concluded that the reproducility of the AECG was low and this reproducibility became lower as the time interval between both AECG's became longer and that hese facts had to be considered when the effect of the antiarrhythmic drugs was evaluated.
Anti-Arrhythmia Agents ; Calcium Channel Blockers ; Cardiac Complexes, Premature ; Electrocardiography, Ambulatory* ; Female ; Heart Diseases ; Humans ; Male ; Myocardial Ischemia

Many investigators have shown that computer analysis of exercise induced ST segment changes in feasible and valid. This technique should make it possible to achieve uniformity of interpretation. Though myocardial ischemic response, arrhythmia, R wave amplitude and heart rate changes are documented by CASE exactly, blood pressure change, subjective and objective signs are assessed clinicall only. Therefore, both CASE and clinical analysis are demanded for the precise interpretation of GXT. Two hundred and ten patients, aged 22-68 y/o, were evaluated for comparative analysis between CASE and clinical assessment. The following results were obtained; 1) The sensitiivity of CASE to clinical analysis is 70.2%. 2) Among the 40 cases with ST segment-positive response, 24 cases(60%) had a less than 2mm ST depression and 16 cases(40%) had a more than 2mm ST depression. 3) Among the 40 cases with ST segment-positive response, 30 cases(75%) had a increased in R wave amplitude of 2.8mm in average, while among the 153 cases with GXT-negative response, 61 cases(39.9%) had R wave increase of 1.5mm in average. 4) Increment of systolic blood pressure per MET was 5.6 mmHg. There was no significant difference by age.
Arrhythmias, Cardiac ; Blood Pressure ; Depression ; Heart Rate ; Humans ; Research Personnel

BACKGROUND: The proper management of the patients with hypotention remains a difficult clinical problem. This study was designed to evaluate the efficacy and safety of gepefrin in the treament of symptomatic hypotensive patients in outpatient clinic of university hospital. METHODS: Thirty milligrams of Gepefrin was given twice daily for 4 weeks in 30 patients with hypotension(6 males, 24 females ; 23-60 years of age). Blood pressure, heart rate, subjective symptoms and side effects were checked before medication and at the end of 1st, 2nd, 3rd, 4th week of medication. RESULTS: 1) Grpefrin increased sitting systolic blood pressure significantly(p<0.05) by the end of 1st week and thereafter. 2) Hypotensive symptoms were improved in 76% of hypotensive patients and overall rate of usefulness was 70%. 3) Heart rate did not change significantly. 4) One patient complained of loose bowel movement and another one, of anorexia among 30 study patients and all laboratory parameters were within normal limits before and after drug treatment, thus the rate of safety was 93%. CONCLUSION: Results from this study suggests that gepefrin 60mg daily increases the blood pressure mildly and improves the symptoms moderately in symptomatic hypotensive patients.
Ambulatory Care Facilities ; Anorexia ; Blood Pressure ; Female ; Heart Rate ; Humans ; Hypotension* ; Male ; Quality of Life

The mucoepidermoid carcinoma on the cornea and conjunctival is so rare that only a few cases have been reported worldwide and no case in Korea. We experienced that a patient whose complaint was a protruding mass on the conjunctiva, after tumor removal it was histologically defined as mucoepidermoid carcinoma. So we report a case of conjunctival mucoepidermoid carcinoma involving the cornea, with reviewing reference.
Carcinoma, Mucoepidermoid* ; Conjunctiva ; Cornea* ; Humans ; Korea

PTCA has been widely applied in patients with symptomatic coronary artery disease since 1977. The PTCA was performed on a total of 25 patients (19 men and 6 women) from Feburary 1988 to January 1990 at Inje University Baik Hospital. Their mean age was 51.4+/-10.1 years. The 20 patients had unstable angina, and 5 patients had stable angina. The 6 patients had a previous myocardial infarction. The 17 patients had one vessel disease, 6 patients had two vessel disease and 2 patients had three vessel disease. Primary success was achieved in 24 of 25 patients. The mean degree of stenosis was reduced from 80.7+/-2.9% to 16.2+/-3.3% (p<0.01). After PTCA, pain was relieved or subsided in all patients. In 6 patients, mild chest pain has reccured during the short term follow up. Repeat PTCA was performed in 2 of 6 patients successfully. Complications occurred in 3 patients ; coronary artery spasm, ventricular fibrillation and femoral artery hematoma in each patients.
Angina, Stable ; Angina, Unstable ; Angioplasty, Balloon, Coronary* ; Arteries ; Chest Pain ; Constriction, Pathologic ; Coronary Artery Disease* ; Coronary Vessels* ; Femoral Artery ; Follow-Up Studies ; Hematoma ; Humans ; Male ; Myocardial Infarction ; Spasm ; Ventricular Fibrillation

A new hypolipidemic agent, lovastatin, hydroxy-methyl-gultaryl coenzyme A reductase inhibitor was administred to 25 patients with primary hyperlipidemia 20 to 40 mg daily for 12 weeks and sequential changes of serum lipid profile were analysed as follow. 1) Mean average at baseline period of serum total cholesterol, triglyceride, HDL and low desity lipoprotein cholesterol were 271, 179, 51 and 185 mg/dl respectively. 2) Total cholesterol showed 20% decrease at 4th week and 23% decrease at the end of 12th week while low density lipoprotein cholesterol decreased 31% and 33% respectively. 3) Triglyceride dropped 7% at 8th week and 3% at 12th week. High density lipoprotein cholesterol increased 4% at 4th week and showed 2% decrease at the end of study. 4) Only one patient complained of moderate abdominal pain, which subsided after 2 weeks drug withdrawal. In conclusion, lovastatin was well tolerated and effective, in the treatment of primary hyperlipidemia.
Abdominal Pain ; Cholesterol ; Cholesterol, HDL ; Cholesterol, LDL ; Coenzyme A ; Humans ; Hyperlipidemias* ; Lipoproteins ; Lovastatin ; Oxidoreductases ; Triglycerides